Sam Brusco, Associate Editor03.26.24
Getinge and Cook Medical began an exclusive sales and distribution deal for the iCast covered stent system.
iCast has been on the market for 20 years and recently earned U.S. Food and Drug Administration (FDA) premarket approval to treat iliac arterial occlusive disease.
The agreement has a 60-day transition period, after which Cook Medical will assume iCast’s sales, marketing, and distribution rights in the U.S. iCast will continue to be manufactured by Getinge’s legal entity Atrium Medical Corp. in Merrimack, N.H.
“This agreement with Cook Medical ensures that the iCast covered stent system will reach the optimal number of patients who will benefit from it in the United States,” said Patricia Fitch, president of Getinge NA. “This distribution agreement allows Getinge to best serve the U.S. market and accelerate our product innovation pipeline, in alignment with our global business strategy.”
iCast, according to the company, is identical to Getinge’s Advanta V12 covered stent system, which is sold outside the U.S. and has been used by clinicians for 20 years. This announcement does not affect distribution outside of the U.S.
“This product fills the need of a covered stent in our vascular portfolio with a proven technology. iCast has five-year data aligned with our commitment to long-term clinical evidence and predictable results for PAD therapies,” said Mark Breedlove, senior VP of Cook Medical’s Vascular Division. “As Cook evolves to better meet customer needs, we are glad to work with other manufacturers to get products to physicians and patients faster. Our team is excited to support and distribute the iCast covered stent system across the U.S.”
iCast has been on the market for 20 years and recently earned U.S. Food and Drug Administration (FDA) premarket approval to treat iliac arterial occlusive disease.
The agreement has a 60-day transition period, after which Cook Medical will assume iCast’s sales, marketing, and distribution rights in the U.S. iCast will continue to be manufactured by Getinge’s legal entity Atrium Medical Corp. in Merrimack, N.H.
“This agreement with Cook Medical ensures that the iCast covered stent system will reach the optimal number of patients who will benefit from it in the United States,” said Patricia Fitch, president of Getinge NA. “This distribution agreement allows Getinge to best serve the U.S. market and accelerate our product innovation pipeline, in alignment with our global business strategy.”
iCast, according to the company, is identical to Getinge’s Advanta V12 covered stent system, which is sold outside the U.S. and has been used by clinicians for 20 years. This announcement does not affect distribution outside of the U.S.
“This product fills the need of a covered stent in our vascular portfolio with a proven technology. iCast has five-year data aligned with our commitment to long-term clinical evidence and predictable results for PAD therapies,” said Mark Breedlove, senior VP of Cook Medical’s Vascular Division. “As Cook evolves to better meet customer needs, we are glad to work with other manufacturers to get products to physicians and patients faster. Our team is excited to support and distribute the iCast covered stent system across the U.S.”